HIV Prevention Research & Development Investments 2017: Investing to end the epidemic

This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2017, reported funding for HIV prevention R&D decreased by 3.5 percent (US$40 million) from the previous year, falling to US$1.13 billion (Figure 2). This is the fifth consecutive year of decreasing annual investment, with 2017 levels representing the lowest funding since 2005.

Click here for the full archive of past resource tracking reports.

Tracking and Translating the Field